Beyond the Acute Infection: Unraveling Long COVID and Mental Health
It has been six years since COVID-19 first upended our world in 2020, establishing itself as a defining global pandemic of the 21st century. In the early years (2020–2023), the virus caused severe illness and accounted for nearly 9% of all U.S. deaths (Abidin et al., 2025).
Thanks to advancements in treatment and widespread immunity, mortality rates dropped to about 2.5% by the last confirmed tracking year (Ahmad et al., 2024). However, much like the flu, the virus continues to mutate and evade our immune defenses, making it impossible to keep completely at bay.
Worse still, surviving the acute infection is not always the end of the story. A significant shadow cast by the pandemic is Long COVID (also known as post-COVID-19 condition or PASC). Current estimates indicate that roughly 10% to 26% of adults struggle with this lingering syndrome (Mandel et al., 2025).
What Is Long COVID and Why Does It Happen?
According to a World Health Organization (WHO) Delphi consensus, the post-COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection—typically starting three months from the initial onset, lasting for at least two months, and remaining unexplained by an alternative diagnosis (Soriano et al., 2022). Common physical signs include fatigue, shortness of breath, and cognitive dysfunction that disrupts everyday life.
Researchers believe Long COVID is driven by persistent systemic and localized inflammation. Key biological mechanisms include (Greenhalgh et al., 2024):
Viral Reservoirs: Fragments or active remnants of the virus remaining in tissues and causing ongoing damage.
Viral Reactivation: The reactivation of dormant viruses in the body, such as the Epstein-Barr virus (the virus responsible for mono).
Immune Dysregulation: An overactive immune response that inadvertently damages healthy host tissues.
Vascular Inflammation: Blood vessel inflammation leading to micro-clotting and cellular dysfunction.
The Hidden Toll: How Long COVID Affects Mental Health
The impact of Long COVID extends far beyond physical exhaustion. The American Psychiatric Association (APA) has identified a broad spectrum of neuropsychiatric sequelae linked to the condition (Gillan et al., 2024).
These include:
Cognitive & Neurological Issues: Brain fog, attention problems, headaches, dementia-like cognitive slowing, and profound fatigue.
Mood & Psychiatric Conditions: Anxiety disorders, major mood shifts/disorders, insomnia, substance use challenges, and in severe cases, psychosis.
These symptoms are largely believed to stem from neuroinflammation—low-grade inflammation occurring directly within the central nervous system (Gillan et al., 2024).
What Can We Do About It?
While navigating Long COVID can feel isolating, clinical research is rapidly catching up to offer actionable paths forward.
1. Prevention Through Vaccination
Vaccination remains a powerful shield—not just against severe acute disease, but against subsequent mental health struggles. Data shows a clear protective gap: for every 100,000 people who contracted COVID-19, roughly 1,000 unvaccinated individuals developed new-onset depression, compared to only about 450 among those who were vaccinated (Walker et al., 2024).
2. Behavioral and Lifestyle Interventions
Paced Exercise and CBT: A major systematic review and meta-analysis of over 5,000 patients found that a combination of tailored physical activity/pacing and Cognitive Behavioral Therapy (CBT) serves as one of the most effective interventions for managing post-COVID depressive and anxiety symptoms (He et al., 2023).
Targeted Sleep Hygiene: CBT-I (Cognitive Behavioral Therapy for Insomnia) is the gold standard for tackling persistent sleep disruptions.
Substance Reduction: Avoiding alcohol and illicit drugs is vital, as both can exacerbate neuroinflammation, disrupt restorative sleep, and worsen anxiety or mood instability.
3. Emerging Medical Treatments
Clinicians are evaluating several pharmacological options to target underlying inflammation and neurotransmitter imbalances:
Vortioxetine: A randomized controlled trial (RCT) demonstrated that vortioxetine improved depressive symptoms in post-COVID patients, though its impact on cognition varied (McIntyre et al., 2024).
SSRIs (Selective Serotonin Reuptake Inhibitors): Because Long COVID is heavily linked to reduced serotonin availability, SSRIs are widely utilized. Notably, recent clinical data highlights fluvoxamine as an effective treatment for reducing long COVID-related fatigue and improving quality of life (Reis et al., 2026).
Off-Label Options: Some specialists utilize bupropion or wakefulness-promoting agents (such as methylphenidate, modafinil, and amphetamine salts) to manage severe fatigue and brain fog, though comprehensive long-term safety data for these specific uses are still emerging.
References
Abidin, Z. U., Thirumalareddy, J., Gupta, J. S., & Abdul Jabbar, A. B. (2025). Disparities in COVID-19 mortality in the United States, 2020-2023. BMC Public Health, 25(1), 3257. https://doi.org/10.1186/s12889-025-24530-1
Ahmad, F. B., Cisewski, J. A., & Anderson, R. N. (2024). Mortality in the United States - Provisional Data, 2023. MMWR Morbidity and Mortality Weekly Report, 73(31), 677–681. https://doi.org/10.15585/mmwr.mm7331a1
Gillan, A., Peace, M., Quinn, D., Levenson, J., & Thant, T. (2024). Resource Document on the Neuropsychiatric Symptoms of Subacute and Chronic Long COVID. American Psychiatric Association.
Greenhalgh, T., Sivan, M., Perlowski, A., & Nikolich-Žugich, J. (2024). Long COVID: a clinical update. The Lancet, 404(10453), 707–724. https://doi.org/10.1016/S0140-6736(24)01136-X
He, J., Lin, J., Sun, W., Cheung, T., Cao, Y., Fu, E., Chan, S. H. W., & Tsang, H. W. H. (2023). The effects of psychosocial and behavioral interventions on depressive and anxiety symptoms during the COVID-19 pandemic: a systematic review and meta-analysis. Scientific Reports, 13(1), 19094. https://doi.org/10.1038/s41598-023-45839-0
Mandel, H., Yoo, Y. J., Allen, A. J., et al. (2025). Long COVID Incidence Proportion in Adults and Children Between 2020 and 2024: An Electronic Health Record-Based Study From the RECOVER Initiative. Clinical Infectious Diseases, 80(6), 1247–1261. https://doi.org/10.1093/cid/ciaf046
McIntyre, R. S., Phan, L., Kwan, A. T. H., et al. (2024). Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial. Brain, 147(3), 849–857. https://doi.org/10.1093/brain/awad377
Reis, G., Moreira Silva, E. A. S., Medeiros Silva, D. C., et al. (2026). The Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID: An Adaptive Randomized Trial. Annals of Internal Medicine, 179, 621–628. https://doi.org/10.7326/ANNALS-25-03959
Soriano, J. B., Murthy, S., Marshall, J. C., Relan, P., & Diaz, J. V. (2022). A clinical case definition of post-COVID-19 condition by a Delphi consensus. The Lancet Infectious Diseases, 22(4), e102–e107. https://doi.org/10.1016/S1473-3099(21)00703-9
Walker, V. M., Patalay, P., Cuitun Coronado, J. I., et al. (2024). COVID-19 and Mental Illnesses in Vaccinated and Unvaccinated People. JAMA Psychiatry, 81(11), 1071–1080. https://doi.org/10.1001/jamapsychiatry.2024.2339
